Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | LIG1 | P18858 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7362268 | 0.88 | HPGD (0.44) | HDAC3HDAC4HDAC1HDAC6GRM6 | |
| SCHEMBL5737167 | 0.76 | MAPT (0.42) | HDAC3HDAC1ALDH1A1 | |
| SCHEMBL8549436 | 0.75 | DAO (0.48) | DAOPKMLIG1HDAC3HDAC4 | |
| SCHEMBL4514786 | 0.74 | ALDH1A1 (0.43) | HDAC3HDAC1ALDH1A1HPGD | |
| SCHEMBL9255887 | 0.74 | DAO (0.41) | DAOPKMLIG1ALDH1A1HPGD | |
| SCHEMBL277557 | 0.72 | HPGD (0.46) | HDAC3HDAC4HDAC1HDAC6KDM4E | |
| SCHEMBL2846285 | 0.71 | RIPK1 (0.42) | DAOPKMLIG1HDAC3HDAC4 | |
| SCHEMBL13983930 | 0.70 | CLK1 (0.49) | DAOPKMLIG1HDAC3HDAC4 | |
| SCHEMBL1706932 | 0.70 | HDAC6 (0.38) | HDAC1HDAC6 | |
| SCHEMBL7893713 | 0.69 | DAO (0.54) | DAOPKMLIG1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960594-B2 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | SHIRE BIOCHEM INC. (CA) | 2005-11-01 | — | — | US | disclosed |
| EP-1091952-B1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | IAF BIOCHEM INT (CA) | 2003-10-29 | — | — | EP | disclosed |
| US-20020137947-A1 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | BIOCHEM PHARMA INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1091952-A1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | BIOCHEM PHARMA INC (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000000486-A1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | BIOCHEM PHARMA INC. (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137947-A1 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | ITGB5, ITGB2, ITGA2 | DAO 1048/4885PKM 4279/4885LIG1 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.